David Earl Heppner

Title: David Earl Heppner: Innovator in Asthma Treatment

Introduction

David Earl Heppner is a notable inventor based in Burlington, Vermont. He has made significant contributions to the field of medical science, particularly in the development of treatments for asthma and related conditions. His innovative work focuses on the use of covalent inhibitors to target specific biological pathways.

Latest Patents

Heppner holds a patent for "Covalent inhibitors of dual oxidase 1 (DUOX 1)." This invention relates to inhibitors that can be applied to subjects who have or are at risk for asthma. The patent outlines various methods of application, including pulmonary or topical delivery. The inhibitors may include peptides or other moieties with reactive electrophiles that target cysteine or other residues within DUOX1 to inhibit its activity. Notable examples of suitable inhibitors mentioned in the patent include hydroxynonenal, curcumin, sulforaphane, cinnamaldehyde, dimethyl fumarate, and phenyl vinyl sulfonate.

Career Highlights

Heppner is affiliated with the University of Vermont and State Agricultural College, where he conducts research and develops innovative solutions for health-related issues. His work has the potential to impact the treatment of asthma significantly.

Collaborations

Heppner has collaborated with esteemed colleagues such as Albert Van Der Vliet and Karamatullah Danyal, contributing to a rich environment of research and innovation.

Conclusion

David Earl Heppner's contributions to the field of asthma treatment through his innovative patent demonstrate his commitment to improving health outcomes. His work exemplifies the importance of research and collaboration in advancing medical science.